---
schema_version: "secwatch.filing_event.v1"
accession: "0001625297-25-000064"
form_type: "8-K/A"
ticker: "INDV"
cik: "0001625297"
company_name: "Indivior Pharmaceuticals, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:21:06.053978+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Indivior estimates $105-130M restructuring charges; exits six non-US markets

## Summary
- Total pre-tax restructuring charges estimated at $105-130M, with $65M recognized in Q3 2025.
- Plans to exit markets: UK, Ireland, Sweden, Israel, Finland, Italy under Action Agenda Phase I.
- Expects at least $150M annual operating expense savings starting in 2026.
- Cash portion of charges $73-92M; includes severance, real estate, asset impairments, contract terminations.
- Headcount reductions cost $33-37M; real estate consolidation $15-21M; asset impairments $21-27M.

## SEC filing metadata
- accession: 0001625297-25-000064
- form_type: 8-K/A
- ticker: INDV
- cik: 0001625297
- company_name: Indivior Pharmaceuticals, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000064/0001625297-25-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625297/000162529725000064/indv-20250826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001625297-25-000064
- JSON: https://secwatch.observer/filing/0001625297-25-000064.json
- Plain text: https://secwatch.observer/filing/0001625297-25-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.